Today: 21 May 2026
Browse Category

NASDAQ:PGEN 15 August 2025 - 14 May 2026

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
14 May 2026
·
Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
15 August 2025
···

Stock Market Today

  • SpaceX Files for Largest IPO Ever, Aiming to Raise $80 Billion
    May 20, 2026, 7:07 PM EDT. Elon Musk's SpaceX has filed paperwork for an initial public offering (IPO) expected to be the largest in history, potentially raising about $80 billion. This would surpass Saudi Aramco's 2019 record of $29 billion and could value SpaceX at over $1 trillion. Musk controls 85% of voting power, potentially becoming the world's first trillionaire. The company, known for reusable rockets and its satellite internet service Starlink, merged with Musk's AI firm xAI last year and plans ambitious projects including orbital data centers and moon bases. The IPO highlights the growing investor interest in space and AI-related industries, possibly setting the tone for a wave of tech IPOs including OpenAI and Anthropic.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop